|
|
|
| Effect of Xixian Tongshuan Pills combined with Edaravone in the treatment of ischemic stroke |
| QU Ji LIU Jingfeng LI Bo |
| Department of Internal Medicine-Neurology, Beijing Hepingli Hospital, Beijing 100013, China |
|
|
|
Abstract Objective To explore clinical effect of Xixian Tongshuan Pills combined with Edaravone in the treatment of ischemic stroke. Methods Ninety-eight patients with ischemic stroke admitted to Beijing Hepingli Hospital from March 2017 to December 2018 were selected as research objects, they were divided into control group (49 cases) and study group (49 cases) according to the random number table. Control group was treated with Edaravone, and study group was treated with Xixian Tongshuan Pills and Edaravone. Clinical efficacy, inflammatory factor indexes [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high sensitivity C-reactive protein (hs-CRP)], scale scores [improved Barthel index (BI), National Institutes of Health stroke scale (NIHSS)] and cerebral blood flow indexes (plasma viscosity, hematocrit, fibrinogen) were compared between two groups. The adverse reactions of two groups during the treatment were recorded. Results Total clinical effective rate of study group was higher than that of control group (P < 0.05). The levels of IL-6, TNF-α and hs-CRP in two groups after treatment were lower than those before treatment, and those in study group were lower than those in control group (P < 0.05). The plasma viscosity, hematocrit and fibrinogen of two groups after treatment were lower than those before treatment, and those in study group were lower than those in control group (P < 0.05). BI score of two groups after treatment was higher than that before treatment, and NIHSS score of two groups was lower than that before treatment (P < 0.05), and BI score of study group was higher than that of control group, and NIHSS score of study group was lower than that of control group (P < 0.05). There was no difference in the incidence of adverse reactions between two groups (P > 0.05). Conclusion The effect of Xixian Tongshuan Pills combined with Edaravone in the treatment of ischemic stroke is definite. It can effectively improve inflammatory factors and cerebral blood flow indexes, and has good safety, which has certain clinical application value.
|
|
|
|
|
|
[1] Niimi J，Ueda K，Tasaka K，et al. Are localized lesions in the common carotid artery a risk factor for recurrence of ischemic stroke in patients with symptomatic carotid artery stenosis? [J]. No Shinkei Geka，2019，47（12）：1239-1246.
[2] 杨海蕾，陈晨，屈秋民.社区脑卒中高危人群颈动脉粥样硬化与缺血性脑卒中的关系[J].西安交通大学学报：医学版，2019，40（6）：916-921.
[3] Shaheen MA，Albelali AA，AlKanhal RM，et al. Frequency，risk factors，and outcomes in patients with significant carotid artery disease admitted to King Abdulaziz Medical City，riyadh with ischemic stroke [J]. Neurosciences （Riyadh），2019，24（4）：264-268.
[4] 王玮娜，王志伟，郑俊江，等.急性缺血性脑卒中溶栓后出血性转化与灌注CT微血管通透性的相关性[J].安徽医药，2019，23（12）：2440-2443.
[5] 郝姗姗.豨莶通栓丸治疗中风急性期患者的临床效果分析[J].大家健康，2016，10（5）：38-39.
[6] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[7] 龙璐，王钟明，陈贞，等.急性缺血性脑卒中患者血浆Lp-PLA2水平与颈动脉硬化斑块稳定性及神经功能缺损程度的关系[J].检验医学，2013，28（10）：885-889.
[8] Shah S，Vanclay F，Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation [J]. J Clin Epidemiol，1989，42（8）：703-709.
[9] 冯大志.豨莶通栓丸的药理作用研究[J].科学与财富，2018（26）：164.
[10] van de Graaf RA，Chalos V，van Es ACGM，et al. Periprocedural intravenous heparin during endovascular treatment for ischemic stroke：results from the MR clean registry [J]. Stroke，2019，50（8）：2147-2155.
[11] Wu Y，Yang LW，Zhai XY，et al. A comparison of intracerebral transplantation of RMNE6 cells and MSCs on ischemic stroke models [J]. Neurol India，2019，67（6）：1482-1490.
[12] Watanabe K，Tanaka M，Yuki S，et al. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? [J]. J Clin Biochem Nutr，2018，62（1）：20-38.
[13] 张道旭，李超.高效液相色谱法测定豨莶通栓丸中三七皂苷R1、人参皂苷Rg1和Rb1的含量[J].国际药学研究杂志，2016，43（6）：1160-1163.
[14] Xu J，Wang Y，Wang A，et al. Safety and efficacy of edaravone dexborneol versus edaravone for patients with acute ischaemic stroke：a phase Ⅱ，multicentre，randomised，double-blind，multiple-dose，active-controlled clinical trial [J]. Stroke Vasc Neurol，2019，4（3）：109-114.
[15] 雒银珍，赵博文，陈茜，等.基于分子模拟技术的豨莶通栓制剂调脂作用机制及剂型选择研究[J].中国中药杂志，2019，44（7）：1436-1441.
[16] 杨敏，李宝柱，刘颖.豨莶通栓丸治疗脑梗死患者的疗效观察[J].世界中西医结合杂志，2014，34（8）：876-877， 900.
[17] 李玉雄，郭子运，张雄新.脑卒中后抑郁患者的炎性因子和脑源性神经营养因子水平变化及相关性分析[J].解放军医药杂志，2018，30（12）：101-104.
[18] 郑春雨，于雪峰，陈水林，等.豨莶草水提取物对痛风性关节炎大鼠JNK信号通路影响[J].中国组织工程研究，2018，22（36）：5816-5820.
[19] 殷玥，孙莹，姜珍.豨莶草中两种活性二萜成分在大鼠体内的药动学研究[J].药学学报，2016，51（4）：631-636.
[20] 金今松，徐茂军，金范学.毛梗豨莶草水提取物对大鼠离体胸主动脉环的舒张作用[J].中国保健营养，2015， 25（13）：39-40. |
|
|
|
